Circulating Endothelial Cells as Predictors in Renal Cell Carcinoma Treatment
Author Information
Author(s): Viktor Gruenwald, Gernot Beutel, Susanne Schuch-Jantsch, Christoph Reuter, Philipp Ivanyi, Arnold Ganser, Marion Haubitz
Primary Institution: Hannover Medical School
Hypothesis
Can circulating endothelial cells (CEC) serve as a predictive biomarker for tumor response in renal cell carcinoma patients treated with sunitinib?
Conclusion
The study suggests that an early increase in circulating endothelial cells is associated with a better response to sunitinib treatment in renal cell carcinoma patients.
Supporting Evidence
- Patients with metastatic RCC had significantly higher CEC levels compared to normal controls.
- Sunitinib treatment led to an increase in CEC in patients with progression-free survival above the median.
- Monocyte counts decreased significantly during sunitinib treatment, indicating target inhibition.
Takeaway
Doctors can check the number of special cells in the blood to see if a cancer treatment is working early on.
Methodology
The study analyzed circulating endothelial cells, monocytes, and soluble VEGFR-2 in 26 patients with metastatic RCC receiving sunitinib treatment.
Potential Biases
Potential biases may arise from the lack of external validation and the single-institution study design.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
The study included 26 patients with a mean age of 62 years, consisting of 15 males and 11 females.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website